UroGen Pharma (URGN) Change in Accured Expenses (2017 - 2026)

UroGen Pharma (URGN) has reported Change in Accured Expenses for 10 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Accured Expenses rose 311.74% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 8.07% YoY) and the FY2025 annual result came in at $2.9 million, down 72.96% from the prior year.
• Change in Accured Expenses climbed to $7.6 million in Q1 2026 per URGN's latest filing, from $4.2 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for URGN reached as high as $13.0 million in Q2 2024 and fell as low as -$5.8 million in Q1 2024.
• A 5-year average of $1.6 million and a median of $708000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 427.68% — and 2024, when it surged 1894.36%.
• Year by year, Change in Accured Expenses stood at $4.1 million in 2022, then tumbled by 39.46% to $2.5 million in 2023, then surged by 215.52% to $7.7 million in 2024, then slumped by 45.73% to $4.2 million in 2025, then soared by 81.47% to $7.6 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $7.6 million, $4.2 million, and -$4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.